< Previous page
All
Airlines/Aviation
Auto
Maritime/Shipbuilding
Transportation
Computer Hardware
Computer Networks
Computer Software
Computer/Electronics
Electronic Commerce
Electronic Components
High Tech Security
Internet Technology
Peripherals
Semiconductors
Electronics Gaming
Consumer Electronics
Mobile Entertainment
Multimedia/Online/Internet
Telecommunications
Household/Consumer/Cosmetics
Retail
Supermarkets
Toys
Alternative Energies
Chemical
Mining/Metals
Oil/Energy
Environmental Products & Services
Green Technology
Art
Cosmetics & Personal Care
Entertainment
Fashion
Film & Motion Picture
Jewelry
Banking/Financial Service
Insurance
Workforce Management/Human Resources
Education
Higher Education
Biotechnology
Health Care/Hospital
Infectious Disease Control
Medical Equipment
Medical/Pharmaceuticals
Agriculture
Machinery
Paper/Forest Products/Containers
Textiles
Domestic policy
Legal issues
Sports
Hotels and Resorts
Leisure/Travel/Hotels
Travel
Restaurants
Beer, Wine & Spirits
Beverages
Non-Alcoholic Beverages
Food/Beverages
Advertising
Books
Music
Publishing/Information Service
Television
Trade show news
Real Estate
Construction/Building
Furniture & Furnishings
|
Title only
|
Print
Next page >
88IV - PR Newswire Asia's news - Health Care/Hospital
5
Crescom Launches Global PoC of Pediatric Musculoskeletal AI with Mass General Brigham
Mass General Brigham Department of Radiology Begins Clinical Validation and Utility of Three MediAI Pediatric Solutions ...
2026-06-16T
Health Care/Hospital
Medical Equipment
Medical/Pharmaceuticals
2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
Revolutionizing Treatments for Blood Cancers and Solid Tumors ...
2026-06-16T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia 500,000-1 million ...
2026-06-16T
Health Care/Hospital
Medical/Pharmaceuticals
Waterdrop Inc. Announces First Quarter 2026 Unaudited Financial Results
BEIJING , June 16, 2026 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare ...
2026-06-16T
Banking/Financial Service
Computer/Electronics
Health Care/Hospital
DuPont to Unveil New Tyvek® Innovation at Safe@Work 2026 in Thailand
New Tyvek® innovation designed to support worker safety and comfort across ASEAN ...
2026-06-16T
Chemical
Computer/Electronics
Health Care/Hospital
Global AI Healthcare Set for Rapid Expansion in 2026 as Xunfei Healthcare (2506.HK) Launches V3.5 Upgrade for Scalable Real-World Applications
HONG KONG , June 16, 2026 /PRNewswire/ -- Xunfei Healthcare (2506.HK) officially launched Xunfei Spark Medical Model V3.5 on June 9. The upgrade focuses on two core areas of urgent demand: clinical diagnosis ...
2026-06-16T
Computer/Electronics
Health Care/Hospital
Informa Markets and Thailand's Health Ministry Join Forces To Deliver a Successful Edition of International Healthcare Week 2026 in Bangkok
BANGKOK , June 16, 2026 /PRNewswire/ -- Informa Markets joins forces with Thailand's Department of Health Service Support (DHSS) to unveil International Healthcare Week 2026, a transformative regional ...
2026-06-16T
Health Care/Hospital
Medical/Pharmaceuticals
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia 500,000-1 million ...
2026-06-16T
Health Care/Hospital
Medical/Pharmaceuticals
Minghui Pharmaceutical Presents Compelling Phase I/II Results for MHB018A, a Novel Subcutaneous Anti-IGF-1R Antibody for Thyroid Eye Disease, in an Oral Presentation at ENDO 2026, the Endocrine Society's Annual Meeting
MHB018A demonstrated outstanding clinical activity in both active and chronic thyroid eye disease At 450 mg Q4W, MHB018A achieved a remarkable 81% proptosis response at Week 12 in active TED and a ...
2026-06-16T
Biotechnology
Health Care/Hospital
Medical/Pharmaceuticals
Frost & Sullivan Institute Celebrates Visionary Companies Addressing the World's Most Pressing Challenges
SILICON VALLEY, Calif. , June 16, 2026 /PRNewswire/ -- The Frost & Sullivan Institute is pleased to present the 2026 Visionary Growth Leadership Best Practices Recognition, celebrating leading enterprises ...
2026-06-16T
Computer/Electronics
Health Care/Hospital
< Previous page
Next page >
Disclaimer :
In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.